accountPRINCETON, N.J. - Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal second-quarter loss Monday on higher research and development costs. The company lost $19.9 million, or 55 cents per share, in the quarter ended March 31, compared with a...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pharmasset 2Q loss widens on costs
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account